PTS Diagnostics Product Discontinuation Notice

Why It Matters

Laboratories that rely on A1CNow+ controls must adjust procurement to Nova‑One products, affecting testing workflows and highlighting broader supply‑chain volatility in point‑of‑care diabetes diagnostics.

Key Takeaways

• Discontinuation effective June 1, 2026 in US and Maldives.
• Supply‑chain limits, not quality issues, drive the product phase‑out.
• Nova‑One A1C controls are compatible, ready‑to‑use, and stable 180 days.
• Existing stock remains supported until each lot’s expiration date.

Pulse Analysis

Supply‑chain disruptions have become a recurring theme across the medical‑device sector, and the latest PTS Diagnostics notice underscores how even niche consumables like HbA1c quality‑control materials are vulnerable. The decision to retire A1CNow+ Controls reflects broader logistical bottlenecks rather than any performance flaw, signaling that manufacturers must maintain flexible sourcing strategies to avoid gaps in point‑of‑care testing capabilities.

Nova‑One Diagnostics’ A1C control solutions emerge as the logical replacement, offering liquid, ready‑to‑use material that mimics patient samples and includes both normal and abnormal levels. Their 180‑day refrigerated shelf life and inclusion of sample‑mounting slides simplify laboratory workflows, reducing the need for reconstitution steps. Because the controls are engineered for the A1CNow+ platform, transition costs are minimal, allowing clinics to maintain continuity in diabetes monitoring without extensive retraining or equipment changes.

The broader market implication is a subtle shift toward consolidated supply chains and fewer proprietary consumables. As providers adopt Nova‑One’s offering, distributors may see increased demand for compatible control kits, potentially prompting other manufacturers to revisit their product portfolios. Healthcare purchasers should evaluate inventory buffers, negotiate multi‑year agreements where feasible, and monitor regulatory updates to ensure uninterrupted quality‑control testing in an environment where supply volatility remains a constant risk.